Jacqui Grey

Loading Events

Jacqui Grey

Jacqui Grey

Managing Director, EMEA
NeuroLeadership Institute

Jacqui is MD Europe for the NeuroLeadership Institute, her career spans law, HR (previously FVP EMEA for Merrill Lynch) Executive Coaching and Change Consultancy. She is known for her work on innovative leadership programmes and Board level Executive Mentoring for FTSE 100 companies. She has a doctorate in Executive Anxiety and a Masters in Top Team development. She was previously a Board Member of Opportunity Now, presents regularly at Global leadership and women’s conferences and has published a book Executive Advantage – Resilient leadership for 21st Century Organisations © (published February 2013 by Kogan Page). She has been a guest lecturer at Cranfield, IE Business School, LBS and more and writes regularly for management magazines on Leadership and works closely with a number of CEO, and Leadership Forums.

She specialises in:
• Neuroleadership especially relating to resilience & change
• Neuroleadership and Breaking Bias especially around gender/women on boards
• Neuroleadership and Performance management
• Executive Advantage (Resilience for 21st Century leaders)
• Inclusive Leadership (Addressing Talent shortages & succession planning for global 21st Century organisations)
• Authentic Leadership & Authenticity through storytelling
• Blue rooms (Facilitated brainstorming sessions with top teams and boards)

She has worked for:
• IT and Telecoms (BT, Vodafone, Kcom, Cisco, eBay)
• Financial Services (Merrill Lynch, RBS, Barclays, M&S FS)
• Retailers (Morrisons and M&S)
• Pharmaceuticals (Aventis, KCI, GSK, Shire, UCB)
• Manufacturing (ABF and Kelloggs)
• Media BBC and Vizzavi
• Legal firms

Recent Keynotes:
• Conference Board D&I Network Events 2015/16
• Fast Growth Icons 2016
• ICT HRD Forum 2016
• CDO Forum 2016
• Accenture CHRO Forums 2015/16
• Oracle Modern Business Summit 2015/Performance Management Event 2015
• HR Vision Conference Nov 2014/15
• Various company conference keynotes at global banks, manufacturing, pharmaceutical, property and technology companies 2014/15 (Refs available)